Danger of treatment protocols.
Cucchiara
Brett
B
Messé
Steven
S
Kasner
Scott E
SE
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001037:Aphasia / Q000209:etiology; D002545:Brain Ischemia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000451:nursing; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging; D002544:Cerebral Infarction / Q000000981:diagnostic imaging / Q000209:etiology; D002985:Clinical Protocols; D000075202:Contraindications; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019983:Guideline Adherence; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008508:Medication Errors; D010291:Paresis / Q000209:etiology; D010296:Parietal Lobe / Q000098:blood supply / Q000000981:diagnostic imaging; D013702:Temporal Lobe / Q000098:blood supply / Q000000981:diagnostic imaging; D013788:Thalamus / Q000098:blood supply* / Q000000981:diagnostic imaging; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin; D010959:Tissue Plasminogen Activator